125 related articles for article (PubMed ID: 20449881)
1. Reevaluating erythropoiesis-stimulating agents.
Cotter DJ
N Engl J Med; 2010 May; 362(18):1743; author reply 1743-4. PubMed ID: 20449881
[No Abstract] [Full Text] [Related]
2. Reevaluating erythropoiesis-stimulating agents.
Kestenbaum B
N Engl J Med; 2010 May; 362(18):1742; author reply 1743-4. PubMed ID: 20445190
[No Abstract] [Full Text] [Related]
3. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
Steensma DP
J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
[No Abstract] [Full Text] [Related]
4. The FDA black box for EPO: what should nephrologists do?
Singh AK
Nephrol News Issues; 2007 May; 21(6):55-6, 58-9. PubMed ID: 17518125
[No Abstract] [Full Text] [Related]
5. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
Khuri FR
N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
[No Abstract] [Full Text] [Related]
6. Safety concerns for two big anemia drugs.
Nursing; 2008 Oct; 38(10):12. PubMed ID: 18812980
[No Abstract] [Full Text] [Related]
7. Erythropoiesis-stimulating agents in cancer.
Arcasoy MO
J Clin Oncol; 2008 Jun; 26(18):3097-8; author reply 3098-100. PubMed ID: 18565902
[No Abstract] [Full Text] [Related]
8. Erythropoietin: the swinging pendulum.
Oster HS; Neumann D; Hoffman M; Mittelman M
Leuk Res; 2012 Aug; 36(8):939-44. PubMed ID: 22579365
[TBL] [Abstract][Full Text] [Related]
9. Reevaluating erythropoiesis-stimulating agents.
Kimmel PL; Malozowski S
N Engl J Med; 2010 May; 362(18):1742-3; author reply 1743-4. PubMed ID: 20449880
[No Abstract] [Full Text] [Related]
10. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
Walker RG
Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
[No Abstract] [Full Text] [Related]
11. FDA finalizes REMS program for ESAs; Amgen continues to study risks.
Brower V
J Natl Cancer Inst; 2010 May; 102(9):592-3. PubMed ID: 20421565
[No Abstract] [Full Text] [Related]
12. The FDA, stocks, black boxes and ESAs.
Spry L
Nephrol News Issues; 2007 May; 21(6):53-4. PubMed ID: 17518124
[No Abstract] [Full Text] [Related]
13. Reaction from renal associations. Renal Physicians Association.
Blaser R
Nephrol News Issues; 2007 May; 21(6):61-2, 64. PubMed ID: 17518126
[No Abstract] [Full Text] [Related]
14. ESAs further restricted, but debate continues.
Brower V
J Natl Cancer Inst; 2008 Oct; 100(19):1344-51. PubMed ID: 18812542
[No Abstract] [Full Text] [Related]
15. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
Winkelmayer WC
J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
[No Abstract] [Full Text] [Related]
16. No TREATment with darbepoetin dosed to hemoglobin 13 grams per deciliter in type 2 diabetes with pre-dialysis chronic kidney disease--safety warnings for erythropoiesis-stimulating agents.
Curtiss FR; Fairman KA
J Manag Care Pharm; 2009; 15(9):759-65. PubMed ID: 19954267
[No Abstract] [Full Text] [Related]
17. CERA: third-generation erythropoiesis-stimulating agent.
Topf JM
Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
[TBL] [Abstract][Full Text] [Related]
18. Rebates for anti-anemia drugs draw response from FDA, CMS.
Sipkoff M
Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
[No Abstract] [Full Text] [Related]
19. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
Fatodu H
Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
[TBL] [Abstract][Full Text] [Related]
20. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
